Cancer Genetics Inc. (CGIX)

0.21
NASDAQ : Health Services
Prev Close 0.21
Day Low/High 0.20 / 0.22
52 Wk Low/High 0.20 / 1.30
Avg Volume 1.52M
Exchange NASDAQ
Shares Outstanding 56.28M
Market Cap 11.80M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Cancer Genetics' Proprietary IVD For Cervical Cancer, FHACT(R), Receives CE

Cancer Genetics' Proprietary IVD For Cervical Cancer, FHACT(R), Receives CE

CE Marking Allows CGI's DNA-FISH Probe, FHACT(R), to be Widely Marketed in European Economic Area, Which Covers 31 Countries

Cancer Genetics Reports Second Quarter 2014 Financial Results

Cancer Genetics Reports Second Quarter 2014 Financial Results

Conference Call Today at 8:30 a.m. Eastern / 5:30 a.m. Pacific

Cancer Genetics, Inc. Releases The Only Comprehensive Genomic Test To Diagnose & Stratify The Most Common Form Of Leukemia (CLL)

Cancer Genetics, Inc. Releases The Only Comprehensive Genomic Test To Diagnose & Stratify The Most Common Form Of Leukemia (CLL)

CGI's Proprietary Genomic Panel for Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) is Now Licensed to Report Out Risk Stratification of Patients Into Three Distinct Groups

Ratings Changes Today

Upgrades: AMCX, AWRE, IXYS, LMNR, MMYT, MPAA, NATI, PLPM, SGOC, TCPC Downgrades: CGIX, GPRC, NRT, PRSS Initiations: AMBI, TEP Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

Upgrades: ANCB, FRBK, KOS, VOC Downgrades: BIRT, FIG, FRP, GLDC, GLPW, HNH, INS, JBT, KRNY, MCC, PKOH, PKT, QLYS, SCSC, SGA Initiations: CGIX, IBTX, OAKS Read on to get TheStreet Quant Ratings' detailed report:

Risky IPOs: Cancer Genetics, Orchid Island Capital

Risky IPOs: Cancer Genetics, Orchid Island Capital

IPO Desktop President Francis Gaskins believes these IPOs are only for risk takers. Cancer Genetics has lost money and Orchid Island suffers from legal problems.

TheStreet Quant Rating: D- (Sell)